Marinus Pharmaceuticals, Inc. Stock price

Equities

MRNS

US56854Q2003

Pharmaceuticals

Market Closed - Nasdaq 03:59:52 2024-02-22 pm EST 5-day change 1st Jan Change
9.61 USD -1.44% Intraday chart for Marinus Pharmaceuticals, Inc. -3.90% -11.59%
Sales 2023 * 31.87M Sales 2024 * 42.96M Capitalization 525M
Net income 2023 * -135M Net income 2024 * -142M EV / Sales 2023 * 16.5 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 12.2 x
P/E ratio 2023 *
-3.8 x
P/E ratio 2024 *
-4.14 x
Employees 152
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.73%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.44%
1 week-3.90%
Current month-1.33%
1 month-5.04%
3 months+58.06%
6 months+26.61%
Current year-11.59%
More quotes
1 week
9.05
Extreme 9.0506
10.02
1 month
9.05
Extreme 9.0506
10.36
Current year
9.05
Extreme 9.0506
11.26
1 year
5.57
Extreme 5.5704
11.26
3 years
3.47
Extreme 3.465
20.04
5 years
3.08
Extreme 3.08
21.60
10 years
3.08
Extreme 3.08
82.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 18-09-04
Director of Finance/CFO 51 21-04-11
Chief Tech/Sci/R&D Officer 68 19-11-05
Members of the board TitleAgeSince
Director/Board Member 63 08-11-30
Chief Executive Officer 60 18-09-04
Director/Board Member 60 19-12-11
More insiders
Date Price Change Volume
24-02-22 9.62 -1.33% 243,609
24-02-21 9.75 +2.20% 219,595
24-02-20 9.54 -4.22% 308,910
24-02-16 9.96 -0.40% 270,117
24-02-15 10 -0.10% 244,392

Delayed Quote Nasdaq, February 22, 2024 at 03:59 pm EST

More quotes
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of therapeutics for seizure disorders. The Company's commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the United States Food and Drug Administration (FDA) for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase III trials in tuberous sclerosis complex and refractory status epilepticus. The Company's ganaxolone is a neuroactive steroid gamma-aminobutyric acid type A (GABAA) receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. Its ganaxolone is also being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.62 USD
Average target price
20.3 USD
Spread / Average Target
+111.02%
Consensus
1st Jan change Capi.
-11.59% 525 M $
+32.03% 693 B $
+22.22% 552 B $
+2.37% 386 B $
+18.57% 328 B $
+14.05% 312 B $
-6.40% 209 B $
+6.72% 210 B $
-5.32% 197 B $
-4.31% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Marinus Pharmaceuticals, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer